首页 | 本学科首页   官方微博 | 高级检索  
     

两种的晚期胃癌化疗方案的疗效及成本对比研究
引用本文:王芳刘莉洪喆吴琦於健. 两种的晚期胃癌化疗方案的疗效及成本对比研究[J]. 现代生物医学进展, 2012, 12(1): 77-79
作者姓名:王芳刘莉洪喆吴琦於健
作者单位:上海市第二人民医院消化科 上海200011
摘    要:目的:运用药物疗效及经济学方法研究CS辅助化疗与ECF化疗方案,进行成本效果对比分析,为临床合理选用胃癌化疗方案提供参考。方法:选择67例中晚期胃癌患者,随机分为A组(CS,32例)组和B组(ECF组,35例),A组给予CS方案辅助化疗,B组给予ECF方案化疗,3个周期为l疗程,均治疗3个疗程后评价治疗效果及副作用,进行成本效果分析。结果:A组与B组治疗效果比较差异无显著性差异(P>0.05),A组治疗的有较低的相关死亡率,但与B组比较差异无统计学意义(3.13%vs8.57%,P>0.05),A组Ⅲ/Ⅳ度中性粒细胞降低(12.56%vs 37.14%)、Ⅲ/Ⅳ度粒细胞减少性发热(3.13%vs 20.0%)、Ⅲ/Ⅳ度口腔粘膜炎(3.13%vs 22.90%)、肾毒性(15.6%vs 37.10%)、严重低钾血症(6.30%vs 40.0%)的发生率均低于B组(P<0.05)。A组成本较高,并且由于成本增加,有较高的成本效益比。结论:CS方案虽然有较好安全性,但因成本增加,有较高的成本效益比,患者应根据经济能力选择合适的治疗方案。

关 键 词:胃癌  CS方案  S-1  成本效果分析

Cost Ettectiveness Analysis of two Chemotherapy Schemas on AdvancedGastric Carcinoma
WANG Fang,LIU Li,HONG Zhe,WU Qi,YU Jian. Cost Ettectiveness Analysis of two Chemotherapy Schemas on AdvancedGastric Carcinoma[J]. Progress in Modern Biomedicine, 2012, 12(1): 77-79
Authors:WANG Fang  LIU Li  HONG Zhe  WU Qi  YU Jian
Affiliation:(Department of Gastroenterology;Shanghai Second People’s Hospital,Shanghai 200011)
Abstract:Objective: To analyze the cost and ettectiveness of two chemotherapy schemas on advanced gastric carcinoma.Methods: 67 cases with advanced gastric carcinoma are randomized into two groups: group A(CS group,32 cases) and group B(ECF group,35 cas-es),while the group A take CS chemotherapy schema for 3 courses of treatment.The group B take ECF chemotherapy schema for 3 courses of treatment.Analyze the treatment effectiveness,side effect and cost ettectiveness.Results: The treatment effec-tiveness of two chemotherapy schemas has no difference(P>0.05).Group A has lower correlated death rate than group B,but the difference has no sta-tistically significance(P>0.05).The cases in group A have lower rate than group B in Ⅲ/Ⅳ grate neutrophilic granulocyte decline(12.56% vs 37.14%),febrile(3.13% vs 20.0%),Ⅲ/Ⅳgrate oral mucositis(3.13% vs 22.90%),renal toxicity(15.6% vs 37.10%),severe hypokalemia(6.30% vs 40.0%)(P<0.05);Group A has higher cost and cost ettectiveness than group B.Conclusion: CS chemotherapy schema has better safe reliability,higher cost and cost ettectiveness than group B.The patient should choose suitable chemotherapy schemas depending on economic ability.
Keywords:Gastric carcinoma  CS chemotherapy schema  S-1  Cost ettectiveness analysis
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号